Flexibility to meet the needs of patients and practices

Physician-patient choice is at the forefront of the Jelmyto treatment approach1,2

choice of installation

Antegrade or retrograde instillation available1

  • Instilled with the Uroject12 Syringe Lever and a nephrostomy tube or 5- or 7-French ureteral catheter
  • General anesthesia is not required*

choice of location

Administered in the clinic, hospital, or ASC2

  • Can be performed as an outpatient procedure — patients can go home soon after instillation

6 once-weekly instillations with the choice for maintenance therapy (see footnote †)

Instilled as a chilled liquid1‡

  • 4 mg per mL, with total instillation volume based on volumetric measurements using pyelography (not to exceed 15 mL)

Mitomycin for pyelocalyceal solution (Jelmyto) should not be instilled immediately following resection or ablation. Please refer to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and AUA/SUO Guideline for principles of instillation therapy.

Used in 37% of patients for at least one instillation during treatment period. Local anesthesia or sedation was used at the discretion of the physician.
For patients with a complete response, a maximum of 11 instillations can be administered once a month for maintenance therapy.
Prior to administration, JELMYTO must be reconstituted by the pharmacy. On average, pharmacy partners report 45-60 minutes for the reconstitution of JELMYTO. (Individual times may vary.) It can then be stored for up to 96 hours (4 days) at room temperature.1
ASC = ambulatory surgery center.

Featured resources

Download these resources to learn more and to get your appropriate patients started on Jelmyto treatment.

Antegrade Instillation Overview


Instructions for Administration


Nephrostomy Instructions


Instructions for Pharmacy

View more resourcesArrow (right) icon

Versatility in low-grade UTUC

See how Jelmyto is used across different patient presentations

See the regimens
Full Prescribing InformationArrow (right) icon

Indications and Usage

Jelmyto® (mitomycin) for pyelocalyceal solution is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Important Safety Information


Jelmyto is contraindicated in patients with perforation of the bladder or upper urinary tract.

Ureteric Obstruction

Ureteric obstruction, including ureteral stenosis and hydronephrosis, occurred in patients receiving Jelmyto. Monitor patients for signs and symptoms of ureteric obstruction, including flank pain, and fever, and for changes in renal function. Patients who experience obstruction may require transient or long-term ureteral stents or alternative procedures. Withhold or permanently discontinue JELMYTO based on the severity of ureteric obstruction.

Bone Marrow Suppression

The use of Jelmyto can result in bone marrow suppression, particularly thrombocytopenia and neutropenia. The following tests should be obtained prior to each treatment: Platelet count, white blood cell count differential and hemoglobin. Withhold JELMYTO for Grade 2 thrombocytopenia or neutropenia. Permanently discontinue for Grade 3 or greater thrombocytopenia or neutropenia.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, Jelmyto can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with JELMYTO and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with JELMYTO and for 3 months following the last dose.

Common Adverse Reactions

The most common adverse reactions in ≥ 20% of patients treated with Jelmyto were ureteric obstruction, flank pain, urinary tract infection, hematuria, abdominal pain, fatigue, renal dysfunction, nausea, dysuria, and vomiting.

Additional Adverse Reactions Information

Selected clinically relevant adverse reactions in < 10% and ≥ 2% of patients who received Jelmyto include urinary tract inflammation, bladder spasm, urosepsis, hypersensitivity, and instillation site pain.

Use in Specific Populations

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with Jelmyto and for 1 week following the last dose.

Preparation and Administration Information

Jelmyto is for pyelocalyceal use only and not for intravenous use, topical use, or oral administration. Jelmyto must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the JELMYTO Instructions for Pharmacy and administration instructions found in the JELMYTO Instructions for Administration.

Jelmyto may discolor urine to a violet to blue color following the instillation procedure. Advise patients to avoid contact with urine for at least six hours post-instillation, to void urine sitting on a toilet, and to flush the toilet several times after use.

Jelmyto is a hazardous drug. Follow applicable special handling and disposal procedures.

Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.

References: 1. JELMYTO [package insert]. Princeton, NJ: UroGen Pharma, Inc.; 2022. 2. Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020;21(6):776-785.